Metastatic hormone sensitive prostate cancer
Clinical trials for Metastatic hormone sensitive prostate cancer explained in plain language.
Never miss a new study
Get alerted when new Metastatic hormone sensitive prostate cancer trials appear
Sign up with your email to follow new studies for Metastatic hormone sensitive prostate cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First-in-Human biologic JUR-003 put to the test against metastatic prostate cancer
Disease control Not yet recruitingResearchers are running a first-in-human Phase 1 trial of JUR-003, an intravenous biologic, in adults with metastatic prostate cancer. The study has two parts: a dose-escalation phase to find the highest dose people can tolerate, and a dose-expansion phase to look at early anti-t…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase 1 • Sponsor: Juri Biosciences, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can step counts predict treatment success in prostate cancer?
Disease control Not yet recruitingThis study looks at whether daily step counts can help monitor how well vulnerable patients with metastatic hormone-sensitive prostate cancer are doing on a combination of darolutamide and standard hormone therapy. About 80 adults who are frail or have other health issues will we…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase 4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New PET scans aim to spot prostate cancer more clearly
Diagnosis Not yet recruitingThis study tests three new radioactive imaging agents against a standard one for PET/CT scans in 9 men with advanced prostate cancer. The goal is to see which agent best highlights cancer lesions in the body. It is an early-stage imaging study, not a treatment trial.
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Mapping the tumor microenvironment to predict prostate cancer therapy outcomes
Knowledge-focused Not yet recruitingThis study investigates whether detailed molecular mapping of prostate tumors can predict how well men with metastatic hormone-sensitive prostate cancer respond to androgen deprivation therapy (ADT) combined with second-generation hormonal agents like abiraterone or enzalutamide.…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase 2 • Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC